PDS Biotech - רווח נקי למניה בארבעת הרבעונים האחרונים PDSB
PDS Biotechnology is developing partnerships with the NCI and global pharma behemoths to accelerate testing of antiviral and anti-tumor vaccines. Experienced management enjoys market confidence, skillfully preparing projects for the final phases of verification. The business relies on Versamune, which integrates clinics through strict research protocols. This chart of current share prices reflects an EPS of 30.00, confirming the company's status as a developer of immune drugs.
PDSB (PDS Biotechnology Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים
PDS Biotechnology focuses on developing innovative anti-tumor vaccines, which dictates high capital intensity and specific profit patterns during the development stage. The annual percentage growth of EPS TTM reflects the rolling dynamics of net income per share over 12 months, allowing investors to assess the rate of change in profitability and avoid false extrapolations when analyzing the extremes of this chart.
